Cambridge, UK, 25 March 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced it is collaborating with St George’s University Hospital, London, and the European Molecular Genetics Quality Network (EMQN), based within the Manchester Centre for Genomic Medicine at Saint Mary’s Hospital, to develop reference material for non-invasive prenatal testing (NIPT).

The 10th annual Babraham Investor Conference is taking place in Cambridge on 15 May 2019

Babraham 25th March 2018: Now in its 10th year, the one-day Babraham Investor Conference (BIC) will bring together like-minded investors focused on early-stage and scale-up life science and med-tech opportunities across the UK and Europe.

The AMR Centre, a body with public and private investors leading the UK’s response to the global health threat posed by antimicrobial resistance, has received a significant funding package to support the expansion of its pipeline of new drugs to treat drug-resistant infections.

The package totals £2.3m and is led by an investment from LifeArc, one of the UK’s foremost medical research charities. Other backers include Bruntwood SciTech, MGL, and the Greater Manchester and Cheshire Life Sciences Fund.

Developers of pioneering prognostic tools recognised for its innovative product development and contribution to life science discovery

Cambridge, UK, 21 March 2019: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, are delighted to have been awarded the Life Science Innovation award for product development at the annual Business Weekly awards.

Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (“CTA”) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im Gesundheitswesen (BASG), the Austrian Federal Office for Safety in Health Care.

Babraham Research Campus is offering companies seeking funding the opportunity to present at its 10th investor conference

Babraham 18th March 2018: The Babraham Investor Conference (BIC) is back to bring together like-minded investors focussed on early-stage and scale-up life science and med-tech opportunities.

And now, companies seeking funding of between £250K to £20M have the opportunity to pitch to an audience of potential investors on 15 May at the Babraham Research Campus, Cambridge.

Aigenpulse Ltd., (Aigenpulse), a big data technology company which specialises in structuring, integrating and deriving meaning from large, disparate data assets in the life sciences sector, is continuing to strengthen its management team with the addition of Head of Delivery and Head of DevOps.

LOUGHBOROUGH, England (March 13, 2019) – Thermo Fisher Scientific, the world leader in serving science, recently announced the winners of the Fisher Scientific Channel Supplier Awards during its annual Fisher Scientific European Sales Conference held in Poland.

From March 4-7, 2019, almost 750 delegates attended the Fisher Scientific European Sales Conference at the Gołębiewski Hotel, Karpacz, Poland. This was the eighth event of its kind, bringing together delegates from 21 different countries.


Due to its flexibility to be configured to address a wide spectrum of data challenges within the research environment, LabKey Server has long been assumed to be a LIMS system. It's true, LabKey can be used as fundamental sample management / tracking / processing tool. Things are about to get even more interesting !

Evaluation by the Diagnostic Assessment Programme provides independent support and validation of PredictImmune’s first product addressing IBD

Cambridge, UK, 12 March 2019: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced the formal entry of its first product, PredictSURE IBD™, into NICE’s Diagnostic Assessment Programme (DAP).